Connor Clark & Lunn Investment Management Ltd. Has $6.70 Million Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 145.7% in the 3rd quarter, Holdings Channel.com reports. The firm owned 214,864 shares of the specialty pharmaceutical company’s stock after buying an additional 127,420 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Supernus Pharmaceuticals were worth $6,699,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of SUPN. SG Americas Securities LLC bought a new stake in shares of Supernus Pharmaceuticals in the first quarter valued at about $129,000. UniSuper Management Pty Ltd acquired a new position in Supernus Pharmaceuticals in the 1st quarter valued at approximately $514,000. CANADA LIFE ASSURANCE Co raised its holdings in Supernus Pharmaceuticals by 25.4% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 54,441 shares of the specialty pharmaceutical company’s stock valued at $1,854,000 after acquiring an additional 11,019 shares in the last quarter. EntryPoint Capital LLC bought a new stake in shares of Supernus Pharmaceuticals in the 1st quarter worth approximately $43,000. Finally, BOKF NA acquired a new stake in shares of Supernus Pharmaceuticals during the 1st quarter worth approximately $271,000.

Supernus Pharmaceuticals Price Performance

Supernus Pharmaceuticals stock opened at $36.22 on Friday. The business has a 50 day simple moving average of $33.72 and a 200 day simple moving average of $31.10. The company has a market capitalization of $2.00 billion, a PE ratio of 33.85 and a beta of 0.86. Supernus Pharmaceuticals, Inc. has a one year low of $25.53 and a one year high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The company had revenue of $175.70 million during the quarter, compared to analysts’ expectations of $157.35 million. During the same period last year, the business earned ($0.29) earnings per share. The business’s revenue was up 14.2% on a year-over-year basis. Equities analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Analyst Ratings Changes

SUPN has been the subject of a number of recent research reports. StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Cowen reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Finally, Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, SVP Frank Mottola sold 15,000 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.98, for a total value of $554,700.00. Following the completion of the sale, the senior vice president now directly owns 8,200 shares in the company, valued at approximately $303,236. This trade represents a 64.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Georges Gemayel sold 14,213 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.62, for a total value of $520,480.06. Following the completion of the transaction, the director now directly owns 13,315 shares of the company’s stock, valued at $487,595.30. This represents a 51.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 154,213 shares of company stock worth $5,660,180 over the last ninety days. Corporate insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.